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Abstract
Introduction
Haematopoietic stem cell transplantation (HSCT) recipients are at increased risk for severe
infections. This study examined the associations of common oral infections with survival
and infectious complications in HSCT recipients.
Materials and methods
All autologous and allogeneic HSCT recipients transplanted in the University Hospital of
Basel, Switzerland, between 2008 and 2016 and referred to oral infection control pre-HSCT
were included in this retrospective case-control study. All patients had a clinical and a pan-
oramic radiological dental examination taken immediately prior to HSCT. Presence of acute
or chronic oral foci of infections, decayed, missing or filled tooth index (DMFT) and radiologi-
cal attachment loss (RAL) were examined. Survival and infections of the subjects were fol-
lowed up for 6 months post-HSCT.
Results
Altogether 341 allogeneic and 125 autologous HSCT recipients were included in the study.
Within 6 months post-HSCT, 47 (14%) of the allogeneic and 4 (3%) of the autologous recipi-
ents died. Oral foci of infections (acute or chronic), DMFT or periodontitis pre-HSCT were
not associated with survival 6 months post-HSCT. Oral foci of infections were also not asso-
ciated with hospital treated infectious diseases or blood culture positive bacteremia during
the 6 month follow-up period. Untreated oral foci of infections were not associated with sur-
vival or severe infectious complications within 6 months post-HSCT.
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Conclusion
The results of this study suggest that radical dental interventions to chronic oral infections
could be postponed until post-HSCT.
Introduction
Haematopoietic stem cell transplantation (HSCT) is a widely used potentially curative treat-
ment for severe haematological diseases including various types of haemato-oncologic dis-
eases. During HSCT, high-dose chemotherapy with or without total body irradiation is
utilised to eradicate malignant cells and to produce myelosuppression and immunosuppres-
sion [1]. Due to improvements in the transplantation procedures, the number of long-term
survivors is constantly increasing [2]. Nevertheless, HSCT remains associated with consider-
able acute and long-term morbidities, such as graft-versus-host disease (GvHD), organ dys-
function and secondary malignancies. Due to increased survival rates, less severe symptoms
are common and gaining more clinical importance. [3–5].
There is increasing evidence that HSCT can cause distressing acute and long-term side
effects in the oral cavity, affecting the general wellbeing and quality of life of the patients [5–
11]. Previous studies have mostly focused on symptoms related to GvHD, including mucositis
and hyposalivation. However, only a few studies have examined the prevalence and conse-
quences of common oral infections in HSCT recipients. Consequently, the existing protocols
used for managing oral diseases and associated infectious complications are, hitherto, based
on extrapolations from clinical studies and experience among other oncologic diseases or their
treatment protocols. These include head and neck cancer and solid organ transplantations
[12]. Such extrapolations have revealed dental and oral medicine treatment protocols that dif-
fer remarkably between institutions worldwide [13].
In HSCT, strong immunosuppression is mandatory, and radical dental treatment is there-
fore commonly utilised [14]. This approach has been supported for decades by the National
Institute of Health consensus statement on oral complications of cancer therapy (1989), which
states that dental foci are potential sources of systemic infections that need to be eliminated or
ameliorated before the commencement of an anticancer therapy. Using a decision analysis
method, it has been estimated that dental treatment prior to HSCT may reduce systemic infec-
tions by 30% [15]. However, evidence on the benefits of dental treatments pre-HSCT is scarce
and partly controversial [16]. Thus, a relatively conservative approach, with an emphasis on
good oral hygiene and basic oral care, has been advised in a guideline concerning dental care
among HSCT patients by the established MASCC/ISOO collaboration [13]. However, much
research is needed to provide robust scientific evidence to support the guidelines, and to unify
the oral treatment protocols prior, during and after HSCT.
This study examined the associations of common oral infections with survival and infec-
tious complications in HSCT recipients. The hypothesis, based on our clinical experience and
studies with comparable populations, was that oral foci of infection do in general not predis-
pose to severe systemic complications post-HSCT, and they can be left untreated pre-HSCT
[17].
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Materials and methods
This retrospective study was approved by the Ethikkommission Nordwest- und Zentralsch-
weiz (EKNZ), Switzerland (Ref. Nr. EKNZ:311–10). The study was conducted in the Univer-
sity Hospital of Basel and in the University Center of Dental Medicine Basel, University of
Basel, Switzerland. All 446 consecutive adult (>16 years) HSCT recipients transplanted
between 1st of January 2008 and 31st of December 2016, and referred to oral infection control
pre-HSCT, were included in the study. All data collected from medical records were fully
anonymized before accessed. At that time, most patients had already been treated for their
underlying disease using standard chemotherapy schemas and had received conditioning che-
motherapy either with or without TBI, as previously described [11].
All relevant medical data including stem cell source, total body irradiation, survival and
cause of death of the non-survivors were examined. GvHD (GvHD) was graded according to
standard grading crite,ria and considered as acute (aGvHD) if the onset of the disease was
<100 days post-HSCT. Additionally, infections diagnosed and treated in the hospital within 6
months post-HSCT were examined, and grouped as: 1. any infection, 2. pneumonia, 3. gut
infection, or 4. bacterial/fungal/viral-infection. In the course of HSCT, routine blood samples
related to the treatment protocol were taken several times, and additional samples also when-
ever there were signs of infection. All cases of culture positive bacteremia including the bacte-
rial species were collected.
All study subjects had a thorough dental examination by an experienced dentist pre-HSCT
in the School of Dental Medicine, University Hospital of Basel, Switzerland. A panoramic den-
tal x-ray was taken from all recipients pre-HSCT and observed by a specialist in radiology giv-
ing a written statement. All the dental records, panoramic dental x-rays and associated reports
were re-evaluated, with a particular focus on oral foci of infections. Chronic oral foci of infec-
tions were inspected from the panoramic dental x-rays and grouped as follows: 1. apical peri-
odontitis, 2. caries profunda with the potential for pulp exposure, 3. furcation involvement, 4.
other foci of infection including root remnants, partially erupted wisdom teeth with pericoro-
nitis, initiated endodontic treatment, and cysts. Acute oral foci of infections included: 1. fistula
with purulent drainage, 2. symptomatic periapical granuloma, 3. symptomatic deep caries, 4.
fresh extraction socket and 5. acute periodontal abscess with purulent drainage. Symptomatic
acute oral foci of infections were treated with antibiotics whenever observed prior to the
HSCT. To avoid bacteremia in severely ill patients, periodontitis was only examined in terms
of radiological attachment level (RAL) from the panoramic dental x-rays. Periodontitis was
determined to be present if radiological attachment loss (RAL), e.g. distance between cemen-
toenamel junction (CEJ) and alveolar bone crest, was observed to be> 3mm [18]. The number
of caries lesions and the presence of acute or previous carious lesions (decayed, missing or
filled tooth (DMFT)-index) were examined with thorough dental examination.
Statistics
Main outcomes were survival and infectious complications within 6 months post-HSCT. The
associations of HSCT related factors, oral foci of infections and the presence of acute or
chronic oral diseases with the main outcomes were analysed. Additionally, the associations of
oral foci of infections with hospital treated infections and blood culture positive bacteremia
were examined. Pearson Chi-square (binary outcomes) and Mann-Whitney U tests (others)
were used to determine statistical significance. A p-value of<0.05 was considered as statisti-
cally significant. In the models comparing the associations of different groups of chronic oral
foci of infections (any chronic oral foci, apical periodontitis, caries profunda, furcation
Oral foci of infection and survival post-HSCT
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involvement or other foci) with the outcomes, the Bonferroni correction was used and a p-
value of 0.01 was considered as statistically significant.
Results
Study population
341 allogeneic (mean age at HSCT: 49.4±13.7) and 125 (mean age at HSCT: 55.2±11.3) autolo-
gous HSCT recipients were included in the study (Table 1). Pre-HSCT, 25/341 (7%) of the allo-
geneic recipients had at least one acute oral focus of infection, 167/341 (49%) at least one
chronic oral focus of infection, and 219/341 (64%) periodontitis in terms of RAL>3mm. Mean
decayed, missing or filled tooth (DMFT) index score was 18.7±7.9 (mean±SD). Of the autolo-
gous HSCT recipients, 15/125 (12%) had at least one acute oral focus of infection, 74/125
(59%) had at least one chronic oral focus of infection, and 96/125 (77%) had periodontitis in
terms of RAL>3mm. Mean DMFT was 20.1±7.5 (mean±SD) (Table 2.).
Within 6 months post-HSCT, 47/341 (14%) allogeneic and 4/125 (3%) autologous HSCT
recipients died. Six allogeneic recipients died within the first 30 days post-HSCT. There were
no statistically significant differences between the survivors and non-survivors in terms of
transplant-related factors or covariates, including age, sex, smoking, TBI, ablative conditioning
or diagnosis. Among allogeneic HSCT recipients, grade IV acute GvHD was associated with
death within 6 months post-HSCT (P:<0.001), whereas grade I acute GvHD was associated
with survival (P: 0.02). (Table 1.)
Oral foci of infections and patients’ survival
Acute and chronic oral foci of infections, periodontitis and DMFT, were not associated with
survival at 6 months post-HSCT among allogeneic HSCT recipients (Table 2). Only 4/125
autologous HSCT recipients died within 6 months post-HSCT, and no statistical analysis was
carried out
Oral foci of infections and hospital treated infectious diseases
There were no associations between any of the oral foci of infections and any infectious dis-
eases (any infection, pneumonia, gut infection, or bacterial/fungal/viral-infection) (Table 3).
Among allogeneic HSCT recipients, there was initially a weak association (P = 0.032) between
caries profunda and pneumonia. However, after the Bonferroni correction, the association did
not reach statistical significance.
Oral foci of infections and bacteremia
86/341 (25%) of the allogeneic and 11/125 (9%) of the autologous HSCT recipients had blood
culture positive bacteremia. The most common species were Escherichia coli and Staphylococ-
cus epidermidis. 5/341 (1%) of the allogeneic and 3 (2%) of the autologous HSCT recipients
had oral Streptococcus mitis group or Streptococcus salivarius positive blood cultures. Among
autologous HSCT recipients, no associations between chronic oral foci of infections and septic
infections were observed. Among autologous HSCT recipients, the presence of “any” chronic
oral foci of infection and the presence of “other” foci of infection (root remnants, partially
erupted wisdom teeth with pericoronitis, initiated endodontic treatment, or cysts) were ini-
tially observed to be associated with bacteremia (P-values: 0.025 and 0.037, respectively). How-
ever, after the Bonferroni correction, these associations did not reach statistical significance
(Table 4).
Oral foci of infection and survival post-HSCT
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Table 1. Descriptives of the disease and transplant-related factors of the allogeneic and autologous HSCT recipients.
Allogeneic HSCT recipients Autologous HSCT recipients
Survival <6mo Survival >6mo P-value Survival <6mo Survival >6mo P-value
(n = 47) (n = 294) (n = 4) (n = 121)
Male 26 (55%) 170 (58%) 0,75 3 (75%) 79 (65%) 0,69
Female 21 (45%) 124 (42%) 1 (25%) 42 (35%)
Age (mean) 47,6 49,8 0,32 55,5 55,2 0,96
Smoker 34,2% 49,1% 0,30 25% 54,5% 0,01
Diagnosis:
AML 36,2% 30,6% 0,45 50% 3,3% <0,001
ALL 14,9% 14,3% 0,91
PCD 8,5% 10,2% 0,72 58,7%
MH 2,1% 1,9% 0,69 3,3%
NHL 14,9% 8,5% 0,16 25% 26,4% 0,98
MPN 1,9% 7,5% 0,14
MDS 14,9% 11,6% 0,52 0,8%
BMF 4,3% 2,4% 0,46
Other 2,6% 13% 0,12 25% 7,5% 0,23
Ablative conditioning 80,9% 79,3% 0,60 75% 99,1% 0,87
TBI 51,1% 42,9% 0,22 0% 2,5% 0,75
aGVHD:
no 48,9% 45,6% 0,67
grade 1 8,5% 23,8% 0,02
grade 2 10,6% 21,8% 0,08
grade 3 12,8% 7,1% 0,19
AML: Acute Myeloid Leukaemia, ALL: Acute Lymphoblastic Leukaemia, PCD: Plasma Cell Dysplasia, MH: Hodging Lymphoma, NHL: Non-Hodging-Lymphoma,
MPN: Myeloproliferative Neoplasm, MDS Myelodysplastic Syndrome, BMF: Bone Marrow Failure.
https://doi.org/10.1371/journal.pone.0225099.t001
Table 2. Allogeneic HSCT recipients with the presence of oral foci of infection and oral diseases according to six
months survival.
Baseline presence of: Survival <6mo post-HSCT
(n = 47)
Survival >6mo post-HSCT
(n = 294)
P-value�
Acute oral foci of infection (n) 3 22 0,788
Chronic oral foci of infection
(n)
25 142 0,553
Periapical pathology (n) 11 74 0,795
Caries profunda (n) 8 31 0,195
Furcation involvement (n) 11 60 0,639
Other foci (n) 8 28 0,120
Number of foci (mean) 1,5 1,1 0,464
Peridontitis (n) 26 193 0,170
RAL (mean) 4,8 5,0 0,411
DMFT (mean) 18,4 18,8 0,760
�binary outcomes: Pearson Chi-squere; Continuous varriables: Mann-Whitney U test or t-test.
https://doi.org/10.1371/journal.pone.0225099.t002
Oral foci of infection and survival post-HSCT
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Discussion
This retrospective study examined the associations of common oral infections with survival
and infectious complications in auto- and allogeneic HSCT recipients. The results of the study
showed acute and chronic oral foci of infections, DMFT and periodontitis to not be associated
with survival or infectious complications including sepsis during the 6-month follow-up
period.
The percentage of participants who died within 6 months post-HSCT was 14% among allo-
geneic and 3% among autologous HSCT recipients. Among the allogeneic HSCT recipients,
there were no statistically significant differences between the survivors and non-survivors in
terms of age, sex, smoking or transplant-related factors (TBI, ablative conditioning or diagno-
sis). In line with previous findings, also in this study the severity of acute graft-versus-host dis-
ease (aGvHD) was associated with post-transplant survival [19,20]. Mild, grade I aGvHD was
associated with survival, whereas severe, grade IV aGvHD was associated with death within 6
months post-HSCT. This finding highlights the complexity of the immunological effects of
GvHD. Mild aGvHD may improve survival by decreasing the risk of disease relapse by
enhancing graft versus malignancy. On the other hand, severe aGvHD increases mortality by
causing organ failure, and predisposes the recipient to life-threatening infections. Within the
limits of this study, oral mucositis or presence of oral signs of aGvHD could not be studied.
Acute or chronic oral foci of infections could predispose to these disorders of oral mucosa,
and further studies are thus warranted.
It is currently unclear which oral infectious diseases should be considered as oral foci of
infections and would need to be eliminated prior to high-dose chemotherapy [16].
Table 3. Association of having chronic oral foci of infection with hospital treated infectious diseases 0–6 months post-HSCT.
Baseline presence of: Allogeneic (n = 341) Autologous (n = 125)
with infection (n) with infection (n)
Any oral foci� yes 101 25
no 98 15
Periodontitis� yes 126 31
no 73 9
Acute oral infection� yes 14 6
no 185 34
� Chi-square: P-value >0.05.
https://doi.org/10.1371/journal.pone.0225099.t003
Table 4. Association of having oral foci of infection with blood culture positive bacteremia within six months post-HSCT.
Baseline presence of: Allogeneic (n = 341) with bacteremia (n) Autologous (n = 125) with bacteremia (n)
Any oral foci yes 39 10��
no 47 1��
Periodontitis� yes 52 11
no 34 0
Acute oral infection� yes 5 3
no 81 8
� Chi-square: P-value s>0.05.
�� P-value: 0,025.
��� P-value: 0,037.
https://doi.org/10.1371/journal.pone.0225099.t004
Oral foci of infection and survival post-HSCT
PLOS ONE | https://doi.org/10.1371/journal.pone.0225099 December 18, 2019 6 / 10
Additionally, evidence on the benefits of dental treatments before high-dose chemotherapy
and HSCT is scarce. Despite the lack of evidence, it is commonly recommended that oral foci
of infections should be eliminated, since expected neutropenia during chemotherapy, and
especially during the full intensity conditioning regimen pre-HSCT, predisposes patients to a
spread of infection [10,14,21]. However, patients diagnosed with acute haematological malig-
nancies, particularly acute myeloid leukaemia and acute lymphoblastic leukaemia, as well as
subjects with multiple myeloma and lymphomas, are often treated with high-dose chemother-
apy and HSCT abruptly in a salvage setting. Thus, there is often no time pre-HSCT for dental
treatments, and they ought not to cause delay to the cancer therapy [10].
In our clinic, all HSCT recipients are referred to a dental examination, which is commonly
conducted only a few days pre-HSCT. In this study, acute oral foci of infection were observed
in 7% of the allogeneic and 12% of the autologous HSCT recipients, and at least one chronic
oral focus of infection in 49% of the allogeneic and 64% of the autologous HSCT recipients.
Due to myelo- and immunosuppression, all elective dental treatments are postponed. Thus, all
subjects with chronic oral foci of infection proceed into transplantation. However, neither
acute nor chronic oral foci of infections were associated with survival at 6 months post-HSCT
in this study. Only one previous study concerning the associations of oral foci of infections
with survival post-HSCT was found. In line with our results, in that study with 58 allogeneic or
autologous HSCT recipients, no statistically significant correlations of oral foci of infections
with infections and survival rate post-HSCT were observed [22].
Similarly to the survival, no associations of the examined oral infections with the hospital
treated infectious diseases or blood culture positive bacteremia were observed. The most com-
mon species in the blood cultures were Escherichia coli and Staphylococcus epidermidis, which
are most often associated with urethritis and venous catheters. Bacterial species that are most
likely to originate from the oral cavity were surprisingly uncommon, as only 5 (1%) of the allo-
geneic and 3 (2%) of the autologous HSCT recipients had oral Streptococcus mitis group or
Streptococcus salivarius positive blood cultures. These results are in line with a previous study
with 35 autologous HSCT recipients, of which 6% had acute and 63% chronic oral foci of infec-
tion [17]. No statistically significant differences were found between recipients with or without
oral foci of infection in terms of duration of neutropenia, fewer or blood culture positive bac-
teremia. Also in that study, oral-related bacterial species were uncommon, as only 1 subject
(3%) was observed with Streptococcus mitis. Another recent study among 184 allogeneic HSCT
recipients reported 28 (15.2%) cases with viridans streptococcal bacteremia. In a more detailed
analysis, 14 strains of Streptococcus mitis (7%) were observed. Viridans streptococcal bacter-
emia was not a risk factor for all-cause mortality up to 60 days following allogeneic HSCT [23].
In the present study, the prevalence of common oral diseases was relatively high at pre-
HSCT. 64% of the allogeneic and 77% of the autologous HSCT recipients had periodontitis in
terms of RAL>3mm, and mean DMFT scores were 18.7 and 20.1, respectively. In our previous
study with 257 healthy Swiss adult subjects, a mean DMFT score of 14.2 was observed [24]. In
addition, we have demonstrated hyposalivation to be common in HSCT recipients already
pre-HSCT [7]. Hyposalivation related to preceding conditioning and chemotherapies can
explain some of the observed oral diseases, the elevated DMFT in particular. Hyposalivation
and the lack of defensive functions due to the alternated composition of saliva, that may be
related to haematological diseases and their systemic treatment, is to be considered as a causa-
tive and in many cases an absolutely unavoidable factor that results in an increasing need of
conservative dentistry. An intriguing recent study found patients with acute leukaemia to have
poor oral health in terms of caries and periodontitis already prior to any treatments [25]. Poor
oral health and high dental treatment needs have been reported also in other studies among
HSCT recipients [26]. However, in this study, poor oral health was not associated with
Oral foci of infection and survival post-HSCT
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survival, as no statistically significant differences in the presence of periodontitis or in DMFT
were observed between the survivors and non-survivors. In another previous study, periodon-
titis was observed in 66% and caries in 72% of the studied 36 HSCT recipients pre-HSCT with-
out any signs or symptoms associated with oral foci of infection while they were
immunosuppressed [27].
Similarly to our recent previous study, also in this study periodontitis was determined indi-
rectly by measuring radiological attachment loss from panoramic radiographs [28]. This
method was selected to avoid bacteremia and to keep the dental visits as short as possible for
the severely ill patients immediately prior to the transplantation. This method can detect only
past or present periodontitis and it misses all signs of early disease. On the other hand, some
patients that already have been treated for periodontitis may have been diagnosed false positive
in terms of RAL>3mm in panoramic radiographs. Thus, the results concerning periodontitis
must be treated with caution. However, and despite this relatively coarse method of periodon-
titis diagnosis, this does not cause bias in the results as both groups were assessed with this
RAL-based manner, and no differences between the survivors and non-survivors among the
HSCT recipients were observed.
With the retrospective data available for this study, duration of neutropenia, fewer episodes,
duration of hospitalization, used prophylaxis and interventions as well as subjective symptoms
including quality of life could not be studied. However, oral diseases may cause morbidities
like these, leading to excessive and/or prolonged hospital treatments, and being subjectively
distressing. Further studies are thus needed to assess the associations of oral diseases with
these kinds of less severe problems.
Within the limits of this study, no associations of acute or chronic oral foci of infections,
DMFT and RAL with survival or infectious complications including sepsis 6 months after
auto- or allogeneic HSCT were observed. Thus, the results support the hypothesis that chronic
oral foci of infections could be left untreated and radical dental interventions postponed until
after the high-intensity oncologic treatmenst have been completed. Pre-HSCT, the emphasis
should be on diagnosis by oral medicine professionals, conservative dental treatments and oral
and systemic prophylaxis.
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